Search hospitals > Texas > Houston
M D Anderson Cancer Center
Claim this profileHouston, Texas 77030
Global Leader in Cancer
Global Leader in Uterine Tumors
Conducts research for T-Lymphoblastic Leukemia/Lymphoma
Conducts research for Skin Cancer
Conducts research for Solid Tumors
6030 reported clinical trials
470 medical researchers
Summary
M D Anderson Cancer Center is a medical facility located in Houston, Texas. This center is recognized for care of Cancer, Uterine Tumors, T-Lymphoblastic Leukemia/Lymphoma, Skin Cancer, Solid Tumors and other specialties. M D Anderson Cancer Center is involved with conducting 6,030 clinical trials across 2,083 conditions. There are 470 research doctors associated with this hospital, such as Najat C. Daw, Sarina Piha-Paul, MD, Funda Meric-Bernstam, MD, and Timothy Yap.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Uterine Tumors
Global LeaderStage IV
Stage III
HER2 positive
Top PIs
Najat C. DawM D Anderson Cancer Center5 years of reported clinical research
Expert in Uterine Tumors
Expert in Cancer
52 reported clinical trials
107 drugs studied
Sarina Piha-Paul, MDMD Anderson Cancer Center7 years of reported clinical research
Expert in Uterine Tumors
Expert in Solid Tumors
36 reported clinical trials
53 drugs studied
Funda Meric-Bernstam, MDM D Anderson Cancer Center15 years of reported clinical research
Expert in Solid Tumors
Expert in Cancer
36 reported clinical trials
99 drugs studied
Timothy YapM D Anderson Cancer Center1 year of reported clinical research
Expert in Uterine Tumors
Expert in Solid Tumors
34 reported clinical trials
56 drugs studied
Clinical Trials running at M D Anderson Cancer Center
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Lung Cancer
Breast Cancer
Cancer
T-Lymphoblastic Leukemia/Lymphoma
Esophageal Adenocarcinoma
Myeloid Leukemia
Uterine Tumors
Skin Cancer
SNDX-5613 + ASTX727 + Venetoclax
for Acute Myeloid Leukemia
Part 1b of this clinical research study is to find the highest tolerable dose of SNDX-5613 that can be given in combination with ASTX727 (a combination of the drugs decitabine/cedazuridine) and venetoclax for patients with acute myeloid leukemia (AML) or those with a mixed phenotype acute leukemia with a myeloid phenotype (MPAL). Part 2 of this study is to learn if the dose of study drugs found in Part 1b can help to control AML/MPAL
Recruiting3 awards Phase 1 & 2
Chelation Therapy
for Acute Myeloid Leukemia
This trial studies if medications that remove metals from the body can help patients with certain types of blood cancer respond better to chemotherapy. It focuses on patients with acute myeloid leukemia or myelodysplastic syndrome. The goal is to see if lowering metal levels can improve treatment outcomes. Iron chelation therapy has been shown to improve survival and quality of life in patients with myelodysplastic syndrome (MDS).
Recruiting3 awards Phase 1
Venetoclax + Azacitidine
for Acute Myeloid Leukemia
This phase II trial studies how well venetoclax and azacitidine work for the treatment of acute myeloid leukemia after stem cell transplantation. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and azacitidine after a stem cell transplant may help control high risk leukemia and prevent it from coming back after the transplant.
Recruiting3 awards Phase 223 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at M D Anderson Cancer Center?
M D Anderson Cancer Center is a medical facility located in Houston, Texas. This center is recognized for care of Cancer, Uterine Tumors, T-Lymphoblastic Leukemia/Lymphoma, Skin Cancer, Solid Tumors and other specialties. M D Anderson Cancer Center is involved with conducting 6,030 clinical trials across 2,083 conditions. There are 470 research doctors associated with this hospital, such as Najat C. Daw, Sarina Piha-Paul, MD, Funda Meric-Bernstam, MD, and Timothy Yap.
Where is M D Anderson Cancer Center located?
**MD Anderson Cancer Center - Houston, Texas**
- **Address:** 6901 Bertner Ave, Houston, Texas
- For directions, take I-69 or US-59 South to reach the center.
- For real-time driving directions to the MD Anderson Mays Clinic, use the Waze app with the address: 1220 Holcombe Blvd.
Who should I call to ask about financial aid or insurance network?
**M D Anderson Cancer Center Financial Assistance and Insurance Information**
- **Insurance Information:** For general insurance inquiries, visit the MD Anderson Cancer Center website or call 877-632-6789 for specific questions.
- **Financial Assistance Program:** Eligible cancer patients can benefit from a financial assistance program. Requirements include residency and financial eligibility.
- **Financial Evaluation and Advocacy:** Schedule a financial evaluation by calling 1.844.MDA.BAPTIST (1.844.632.2278). Financial advocates are available to assist with fulfilling financial responsibilities and accessing government medical assistance programs.
- **Flexible Payment Plans and Pharmaceutical Assistance:** Payment plans may be arranged based on financial status. For assistance with the cost of chemotherapy treatments, contact a patient financial advocate.
- **Insurance and Billing:** For detailed insurance and billing inquiries, contact MD Anderson Cancer Center at 713-792-2991 or 1-800-527-2318 (toll-free).
What insurance does M D Anderson Cancer Center accept?
The University of Texas MD Anderson Cancer Center accepts most insurance plans, excluding Cigna and Health Insurance Exchange Plans. Coverage for treatments may be available for patients enrolled in managed care plans (HMO, PPO, or POS), as well as some Medicare and Medicaid plans. To confirm coverage, contact the hospital directly at 210-450-1000.
What awards or recognition has M D Anderson Cancer Center received?
MD Anderson Cancer Center, located in Houston, Texas, is celebrated for its comprehensive cancer research, including translational, preventative, clinical, and basic science. It is also recognized for its clinical and health services research programs. The center honors exceptional achievements in education and training with awards.